The TNF-related apoptosis-inducing ligand (TRAIL), also known as Apo2L (12), has raised great hopes for a novel, broadly applicable treatment of cancers due to its apparently selective induction of tumor cell apoptosis. This evidence concerns the gene TNFSF10 and neoplasm.